IDR 400.0
(-1.48%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | 696.3 Billion IDR | -7.6% |
2022 | 753.57 Billion IDR | -42.9% |
2021 | 1319.72 Billion IDR | 134.04% |
2020 | 563.88 Billion IDR | 100.14% |
2019 | 281.75 Billion IDR | 6.07% |
2018 | 265.62 Billion IDR | 17.95% |
2017 | 225.2 Billion IDR | 1633.46% |
2016 | 12.99 Billion IDR | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q3 | 249.83 Billion IDR | 33.93% |
2024 Q1 | 147.86 Billion IDR | -62.14% |
2024 Q2 | 186.54 Billion IDR | 26.16% |
2023 Q2 | 127.89 Billion IDR | 31.78% |
2023 FY | 696.3 Billion IDR | -7.6% |
2023 Q3 | 80.83 Billion IDR | -36.8% |
2023 Q4 | 390.52 Billion IDR | 383.13% |
2023 Q1 | 97.05 Billion IDR | -51.23% |
2022 FY | 753.57 Billion IDR | -42.9% |
2022 Q4 | 199 Billion IDR | 77.05% |
2022 Q3 | 112.4 Billion IDR | -34.77% |
2022 Q2 | 172.31 Billion IDR | -36.14% |
2022 Q1 | 269.84 Billion IDR | 15.62% |
2021 Q1 | 228.16 Billion IDR | -46.04% |
2021 FY | 1319.72 Billion IDR | 134.04% |
2021 Q4 | 233.38 Billion IDR | -55.22% |
2021 Q3 | 521.16 Billion IDR | 54.64% |
2021 Q2 | 337.01 Billion IDR | 47.71% |
2020 Q2 | 52.7 Billion IDR | 97.29% |
2020 Q1 | 26.71 Billion IDR | -82.52% |
2020 FY | 563.88 Billion IDR | 100.14% |
2020 Q4 | 422.83 Billion IDR | 586.0% |
2020 Q3 | 61.63 Billion IDR | 16.95% |
2019 Q2 | 35.54 Billion IDR | 34.71% |
2019 FY | 281.75 Billion IDR | 6.07% |
2019 Q1 | 26.38 Billion IDR | 0.0% |
2019 Q3 | 67.01 Billion IDR | 88.52% |
2019 Q4 | 152.79 Billion IDR | 128.0% |
2018 Q1 | 47.59 Billion IDR | 0.0% |
2018 FY | 265.62 Billion IDR | 17.95% |
2017 FY | 225.2 Billion IDR | 1633.46% |
2016 FY | 12.99 Billion IDR | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
PT Enseval Putera Megatrading Tbk. | 28507.87 Billion IDR | 97.558% |
PT Kimia Farma (Persero) Tbk | 9965.03 Billion IDR | 93.013% |
PT Millennium Pharmacon International Tbk | 3363.51 Billion IDR | 79.298% |
PT Soho Global Health Tbk | 8197.75 Billion IDR | 91.506% |